-
Mashup Score: 2
Induction therapy for multiple myeloma with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (d) (VRd) was traditionally administered as bortezomib given twice weekly on a 3 week cycle. A modified schedule of weekly bortezomib has been adopted over time to decrease treatment burden f …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Monoclonal Gammopathy of Clinical Significance (MGCS) and Related Disorders: A Review and the Role of Imaging - 3 month(s) ago
The term monoclonal gammopathy of clinical significance (MGCS) refers to a group of symptomatic monoclonal gammopathies that do not meet the diagnostic criteria for malignant plasma cell disorders, such as multiple myeloma or Waldenström macroglobulinemia. These symptoms are attributable to the paraneoplastic effects of monoclonal immunoglobulins that occur through diverse mechanisms. The presence of symptoms distinguishes MGCS from monoclonal gammopathy of undetermined significance, which lacks significant symptomatic presentation. The presentations of MGCS are manifold, adding to the diagnostic challenge. Clinical suspicion is key for accurate and timely diagnosis. Radiologic imaging can provide pivotal information to guide the diagnosis. In this review, we discuss MGCS from a radiology perspective and highlight pertinent imaging features associated with the disorders.
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 25Check out Mayo Clinic's team fundraising page for Multiple Myeloma Research Foundation - 3 month(s) ago
Please support Mayo Clinic and Dr. Joselle Cook at the MMRF Walk/Run: Twin Cities. We are excited to be a part of this event again, and hope you will join our team!
Source: give.themmrf.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 28
Blood Cancer Journal – Racial disparities in multiple myeloma and access to stem cell transplantation
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20International Myeloma Foundation Announces 2024 Medical Student Scholars for Health Equity in Myeloma - 6 month(s) ago
The International Myeloma Foundation (IMF) is proud to announce its selection of IMF Medical Student Scholars for Health Equity in Myeloma for 2024.
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20International Myeloma Foundation Announces 2024 Medical Student Scholars for Health Equity in Myeloma - 6 month(s) ago
The International Myeloma Foundation (IMF) is proud to announce its selection of IMF Medical Student Scholars for Health Equity in Myeloma for 2024.
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19Hitting Us With Your Best Shot: the Best of ASH Malignant 2023 | ASH News Daily | American Society of Hematology - 11 month(s) ago
Division of Hematology, Mayo Clinic, Rochester, MN Ten years ago, at the 55 th ASH Annual Meeting and Exposition in New Orleans, the headline was, “Excitement Over CAR-Engineered T-cells in Leukemia and Lymphoma” since, for the first time, patients with relapsed refractory lymphoma and B-cell acute lymphoblastic leukemia (ALL) were treated with CD19 chimeric antigen receptors (CARs). The “Best of ASH 2013” also proclaimed imetelstat as the newest disease modifying agent for myelofibrosis which reversed
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Addressing the disparities: the approach to the African American patient with multiple myeloma - 11 month(s) ago
Blood Cancer Journal – Addressing the disparities: the approach to the African American patient with multiple myeloma
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 46Heme: The Double-edged Sickle Sword | ASH News Daily | American Society of Hematology - 12 month(s) ago
Division of Hematology, Mayo Clinic, Rochester, MN I completed medical school in Jamaica where one in 10 people has sickle cell trait and one in 150 has sickle cell disease (SCD). I’ve seen the full range of complications of the various permutations of this devastating hemoglobinopathy: the bone crushing pain of an acute crisis; the terror, anxiety, and pain of acute chest syndrome; and the psychologic impact of the gnawing and ever-present chronic background pain — and that’s just to name a few. For two
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 74
Norwalk, Conn., November 30, 2023 — The Multiple Myeloma Research Foundation (MMRF) announced today the first recipients of its Scholars Program, to improve equity in myeloma research and overall outcomes by increasing workforce diversity.
Source: themmrf.orgCategories: General Medicine News, Hem/OncsTweet
@nihardesai7 Hey great question! Other than cast nephropathy as @VincentRK said, we only give #WEEKLY. See our pub showing SAME EFFICACY & LESS NEUROPATHY with weekly Bortezomib https://t.co/tGPRwAGqfn @MayoMyeloma https://t.co/R6Cx6yAgo2